٠	Substitute for form 1449A/PTO				COMPLETE IF KNOWN
	INFORMATION	DIS	CLOSURE	Application Number	10/520,566
	OF SCIENCENIC DA	7 A TD	DI ICANIT	Filing Date	January 7, 2005
	F ETAKEMENT BY	AP	PLICANI	First Named Inventor	D.J. MacNeil et al.
<i>1</i> F	MAR 24 705 # many sheets			Group Art Unit	
	MAN Guse Thany sheets	s as n	ecessary)	Examiner Name	
	THE TRACE I	of	5	Attorney Docket Number	21141YP
		—			

		_	U.S. PA	TENT DOCUMENTS		
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant	Date of Publication of Cited Document MM-DD-YYYY	
/KW/		5908830		Smith et al.,	06/01/1999	
/KW/		6258837		Fukami et al.	07/10/2001	
/KW/		6326375		Fukami et al.	12/04/2001	
/KW/		6335345		Fukami et al.	01/01/2002	
/KW/		6649624		Fukami et al.	11/18/2003	
/KV	11	2001/0025038		Coffin et al.	09/27/2001	
			1			
-						
			_			
	-					
	<u> </u>					
			-			
						
	 					
	-					
	l					

		Foreign Patent Docu		r documents	
Examiner nitials*	Cite No.	Office Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
/KW		WO 02/38551		F. HOFFMAN-LA ROCHE AG	05/16/2002
/KW/		WO 02/40008		WARNER-LAMBERT COMPANY	05/23/2002
7KW/		WO 02/49648		SCHERING CORPORATION	06/27/2002
/KW/		EP 0 920 864		PFIZER PRODUCTS INC.	06/09/1999
/KW/		WO 03/009845		SCHERING CORPORATION	02/06/2003
/KW/		WO 96/16542		SYNAPTIC PHARMACEUTICAL CORPORATION	06/06/1996
/KW/		WO 97/19682		CORPORATION SYNAPTIC PHARMACEUTICAL CORPORATION	06/05/1997
/KW/		WO 97/20820		NOVARTIS AG	06/12/1997
/KW/		WO 97/20821		NOVARTIS AG	06/12/1997
7KW/	9	WO 97/20822		NOVARTIS AG	06/12/1997

Examiner Signature Date Considered /Kevin Weddington/ (06/05/2007)

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents. P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form * IDS Form* (IDS Folder), Merck & Co., Inc., 09/05/2003

					Tacas des Tractiques Gines, die Grant Tattitus T. Gr	COMMICENCE
•	Substitute for form 1449A/PTO	•		C	OMPLETE IF KNOWN	
	INFORMATION	DISC	LOSURE	Application Number	10/520,566	
	P STANEMENT BY	7 A DD	T TO A NITE	Filing Date	January 7, 2005	
k	A SINENIE	APP	LICANI	First Named Inventor	D.J. MacNeil et al.	
1	NAR 2 (uses many sheet			Group Art Unit		
	(use many sheet	s as nec	essary)	Examiner Name	·	
•	2	of	5	Attorney Docket Number	21141YP	
					· · · · · · · · · · · · · · · · · · ·	

U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY			
		-						
				·	-			
			_					

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Poreign Patent Documer Office Number	nt Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY				
/KW/		WO 97/20823	10 202	NOVARTIS AG	06/12/1997				
/KW/		WO 98/18481		MERCK & CO., Inc.	05/07/1998				
/KW/		WO 98/28427		AMGEN INC.	07/02/1998				
/KW/		WO 99/33801		INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE	07/08/1999				
/KW/		WO 00/66578		PFIZER PRODUCTS INC.	11/09/2000				
/KW/		WO 00/76493		NAJARIAN	12/21/2000				
/KW		WO 01/14376		BANYU PHARMACEUTICAL CO., LTD.	03/01/2001				
/KW/		WO 01/64675		NOVARTIS AG/NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H.	09/07/2001				
/KW/		WO 01/70337		MERCK & CO., Inc.	09/27/2001				
/KW		WO 01/70753		MERCK FROSST CANADA & CO.	09/27/2001				

Date Considered Examiner Signature /Kevin Weddington/ (06/05/2007)

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form* IDS Form* (IDS Folder), Merck & Co., Inc., 09/05/2003

	COMPLETE IF KNOWN
Application Number	10/520,566
Filing Date	January 7, 2005
First Named Inventor	D.J. MacNeil et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	21141YP
	Application Number Filing Date First Named Inventor Group Art Unit Examiner Name

U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.	U.S. Patent Document	Kind Code known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY			
	1							

			FOREI	GN PATENT	DOCUMENTS	
Examiner Initials*	Cite No.	Office	Foreign Patent Document Office Number		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document
			· · · · · · · · · · · · · · · · · · ·	Code (if known)	or Cited Document	MM-DD-YYYY
/KW			WO 02/32897		PFIZER PRODUCTS INC.	04/25/2002
/KW			WO 02/20488		F. HOFFMAN-LA ROCHE AG	03/14/2002
/KW/			WO 02/22592		SCHERING CORPORATION	03/21/2002

Date Considered Examiner Signature /Kevin Weddington/ (06/05/2007)

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form* (IDS Folder), Merck & Co., Inc., 09/05/2003

_					PRICE AND TRUCKIEN OFFICE OF COMMERCE
	Substitute for form 1449B/PTO	•	•		OMPLETE IF KNOWN
	Substitute for form 14498/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/520,566	
/	P ETYCKEMENT DV	A D	DI ICANT	Filing Date	January 7, 2005
		AF	PLICANI	First Named Inventor	D.J. MacNeil et al.
•	MIR 2 1 705 E			Group Art Unit	
	(iii) indirection	as n	ecessary)	Examiner Name	
•	Site 4	of	5	Attorney Docket Number	21141YP
					·

	NON PATENT LITERATURE DOCUMENTS									
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.								
/KW/	AA	Parker et al., Eur. J. of Pharmacology, Vol. 440 (2002), pp. 173-187, "Neuropeptide Y receptors as targets for anti-obesity drug development"								
/KW/	ΑВ	Dax, Drugs of the Future (2002), Vol. 27(3), pp. 273-287, "Small-molecule neuropeptide Y Y5 antagonists"								
/KW/	AC	Ford et al., JAMA (2002), Vol. 287, pp. 356-359, "Prevalence of the metabolic syndrome among US adults"								
/KW/	AD	Gadde, et al., JAMA (2003), Vol. 289, pp. 1820-1825, "Zonisamide for weight loss in obese adults"								
/KW/	AE	Rowland et al., Psychopharmacology (2001), Vol. 159, pp. 111-116, "Effects of the cannabinoid receptor antagonist SR 141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats"								
/KW		Boozer et al., Metabolism, Vol. 50 (2001), pp. 889-893, "Synergy of sibutramine and low-dose leptin in treatment of diet-induced obesity in rats"								
/KW	AG	Matson et al., Am. J. Physiol. Regulatory Integrative Comp. Physiol., Vol. 278 (2000), pp. R882-R890, "Cholecystokinin and leptin act synergistically to reduce body weight"								
/KW/	АН	Kopelman, Nature, Vol. 404 (2000), pp. 635-643, "Obesity as a medical problem"								
/KW/	AI	Davidson et al., JAMA (1999), Vol. 281, pp. 235-242, "Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat"								
/KW/	AJ	de Vos et al., J. Biol. Chem., Vol. 270 (1995), pp. 15958-15961, "Induction of ob gene expression by corticosteroids is accompanied by body weight loss and reduced food intake"								
/KW/	AK	Flier et al., Cell (1998), Vol. 92, pp. 437-440, "Obesity and the hypothalamus: Novel peptides for new pathways"								
· /KW/	AL	Abu-Elheiga et al., Science (2001), Vol. 291, pp. 2613-2616, "Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2"								
/KW/	АМ	Smith et al., Nature Genetics, Vol. 25 (2000), pp. 87-90, "Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat"								
/KW/	AN	Cummings et al., Nature, Vol. 382 (1996), pp. 622-626, "Genetically lean mice result from targeted disruption of the RIIB subunit of protein kinase A"								
/KW/	AO	Wadden et al., Obesity Research, Vol. 8 (2000), pp. 431-437, "Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone"								

Examiner Signature	/Kevin Weddington/ (06/05/2007)	Date Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1	Substitute for form 1449B/PTO			COMPLETE IF KNOWN		
INFORMATION DISCLOSURE		Application Number	10/520,566			
	O.E. ASSAUTENT DV ADDI IC	TA NITT	Filing Date	January 7, 2005		
STARMENT BY APPLICANT	First Named Inventor	D.J. MacNeil et al.				
(use as nany sheets as necessary)		Group Art Unit				
		iry)	Examiner Name			
	TRANS 5 of	5	Attorney Docket Number	21141YP		
•						

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.			
/KW/	Menozzi et al., British J. of Nutrition, Vol. 84 (2000), pp. 515-520, "Resting metabolic rate, fat-free mass and catecholamine excretion during weight loss in female obese patients"				
/KW/	AQ	Sorribas et al., J. Pharm. Pharmacol., Vol. 44 (1992), pp. 1030-1032, "Effects of nicarbazin on intestinal digestion and absorption of nutrients in the rabbit"			
/KW/	AR	Badr et al., Toxicology, Vol. 34 (1985), pp. 333-340, "Potentiation of methotrexate-induced gastrointestinal toxicity by non-steroidal anti-inflammatory drugs (NSAIDs) and vincristine"			
/KW/	AS	Stanley et al., Peptides, Vol. 13 (1992), pp. 581-587, "Evidence for neuropeptide Y mediation of eating produced by food deprivation and for a variant of the Y1 receptor mediating this peptide's effect"			
/KW/	АТ	Guy-Grand et al., The Lancet, Vol. 2 (1989), pp. 1142-1145, "International trial of long-term dexfenfluramine in obesity"			
/KW/	AU	Sahu et al., Trends Endocrinol. Metab., Vol. 4 (1993), pp. 217-224, "Neuropeptidergic regulation of feeding behavior"			
/KW/	AV	Wolf, Nutrition Reviews, Vol. 59, No. 2 (2001), pp. 56-57, "The uncoupling proteins UCP2 and UCP3 in skeletal muscle"			
/KW/ AW Bray et al., Obesity Res., Vol. 7, No. 2 (1999), pp. 189-198, "Sibutramine produces dose-related					
/KW/ AX Douglas et al., Int'l J. of Obesity, Vol. 7 (1983), pp. 591-595, "Plasma phentermine levels, wei					
·					
		e			

Examiner Signature	/Kevin Weddington/ (06/05/2007)	Date Considered	

Se	ubstitute for form 1449A/PTO			COMPLETE IF KNOWN	
I	NFORMATION	DISCLOSURE	Application Number	10/520,566	
	or a greek greek by the total	O I P	Filing Date	January 7, 2005	
3	STATEMENT BY APPLICANT	First Named Inventor	D.J. MacNeil et al.		
		DEC 1 1 2006 &	Group Art Unit	1614	
	(use as many sheet	s necessary)	Examiner Name		
Sheet	1	of 2	Attorney Docket Number	21141YP	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite ·No.	U.S. Patent Document Kind Code (if known)		U.S. Patent Document		
					· · · · · · · · · · · · · · · · · · ·	

				GN PATENT D	OCUMENTS	
			Foreign Patent Documer		None Control of Assistant	Date of Publication of
Examiner Initials*	Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY

Examiner Signature	Date Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw tine through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form* IDS Form* (IDS Folder), Merck & Co., Inc., 8/24/2006

	bstitute for form 1449B/PTO		COMPLETE IF KNOWN	
	NFORMATION	DISCLOSURE	Application Number	10/520,566
	TATERATERIT DS/	OIPE	Filing Date .	January 7, 2005
3	STATEMENT BY APPLICANT		First Named Inventor	D.J. MacNeil et al.
		DEC 11 2006 8	Group Art Unit	1614
	(use as many sheets	CHARLEMAN	Examiner Name	
Sheet	2	of 2	Attorney Docket Number	21141YP

NON PATENT LITERATURE DOCUMENTS						
Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.					
AA	Kanatani et al., Molecular Pharmacology, Vol. 59 (2001), pp. 501-505, "A typical Y1 receptor regulates feeding behaviors:"					
AB	Paper presented at NAASO, Obesity Society Annual Meeting, Boston, MA in October 2006, "NPY5R antagonism does not augment the weight loss efficacy of Orlistat or Sibutramine".					
	*					
	No.					

Examiner Signature	/Kevin Weddington/ (06/05/2007)	Date Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.